<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240612222710&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240612222710&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 13 Jun 2024 02:27:11 +0000</lastbuilddate>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Simultaneous transcatheter aortic and tricuspid valve replacement via bilateral cervical approach</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38865357/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 12:ehae352. doi: 10.1093/eurheartj/ehae352. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38865357/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38865357</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae352>10.1093/eurheartj/ehae352</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38865357</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Yu Zhuang</dc:creator>
<dc:creator>Wei Wang</dc:creator>
<dc:creator>Fanglin Lu</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Simultaneous transcatheter aortic and tricuspid valve replacement via bilateral cervical approach</dc:title>
<dc:identifier>pmid:38865357</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae352</dc:identifier>
</item>
<item>
<title>Interventional occlusion treatment of pulmonary artery-aortic aneurysm residual cavity fistula after aortic repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38865347/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 12:ehae370. doi: 10.1093/eurheartj/ehae370. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38865347/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38865347</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae370>10.1093/eurheartj/ehae370</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38865347</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Zihao Li</dc:creator>
<dc:creator>Hongwei Zhang</dc:creator>
<dc:creator>Simin Lin</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Interventional occlusion treatment of pulmonary artery-aortic aneurysm residual cavity fistula after aortic repair</dc:title>
<dc:identifier>pmid:38865347</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae370</dc:identifier>
</item>
<item>
<title>Perforation of the right ventricle and pulmonary artery embolism by bone cement after percutaneous vertebroplasty</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38865341/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 12:ehae369. doi: 10.1093/eurheartj/ehae369. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38865341/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38865341</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae369>10.1093/eurheartj/ehae369</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38865341</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Shi-Xiong Wu</dc:creator>
<dc:creator>Chen Huang</dc:creator>
<dc:creator>Jing Xu</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Perforation of the right ventricle and pulmonary artery embolism by bone cement after percutaneous vertebroplasty</dc:title>
<dc:identifier>pmid:38865341</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae369</dc:identifier>
</item>
<item>
<title>Non-coding RNA yREX3 from human extracellular vesicles exerts macrophage-mediated cardioprotection via a novel gene-methylating mechanism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38865332/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings highlight the role of a small Y RNA mined from EVs with a novel gene-methylating mechanism.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 12:ehae357. doi: 10.1093/eurheartj/ehae357. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Extracellular vesicles (EVs) secreted by cardiosphere-derived cells exert immunomodulatory effects through the transmission of small non-coding RNAs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The mechanism and role of yREX3, a small Y RNA abundant in EVs in myocardial injury, was investigated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: yREX3 attenuates cardiac ischaemic injury by selective DNA methylation. Synthetic yREX3 encapsulated in lipid nanoparticles triggers broad transcriptomic changes in macrophages, localizes to the nucleus, and mediates epigenetic silencing of protein interacting with C kinase-1 (Pick1) through methylation of upstream CpG sites. Moreover, yREX3 interacts with polypyrimidine tract binding protein 3 (PTBP3) to methylate the Pick1 gene locus in a DNA methyltransferase-dependent manner. Suppression of Pick1 in macrophages potentiates Smad3 signalling and enhances efferocytosis, minimizing heart necrosis in rats with myocardial infarction. Adoptive transfer of Pick1-deficient macrophages recapitulates the cardioprotective effects of yREX3 in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings highlight the role of a small Y RNA mined from EVs with a novel gene-methylating mechanism.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38865332/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38865332</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae357>10.1093/eurheartj/ehae357</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38865332</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Alessandra Ciullo</dc:creator>
<dc:creator>Liang Li</dc:creator>
<dc:creator>Chang Li</dc:creator>
<dc:creator>Kara Tsi</dc:creator>
<dc:creator>Colin Farrell</dc:creator>
<dc:creator>Matteo Pellegrini</dc:creator>
<dc:creator>Eduardo Marbán</dc:creator>
<dc:creator>Ahmed G E Ibrahim</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Non-coding RNA yREX3 from human extracellular vesicles exerts macrophage-mediated cardioprotection via a novel gene-methylating mechanism</dc:title>
<dc:identifier>pmid:38865332</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae357</dc:identifier>
</item>
<item>
<title>Inflammation in cardio-oncology: beyond immunotherapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38865293/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 12:ehae333. doi: 10.1093/eurheartj/ehae333. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38865293/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38865293</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae333>10.1093/eurheartj/ehae333</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38865293</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Anne Lise Ferrara</dc:creator>
<dc:creator>Stefania Loffredo</dc:creator>
<dc:creator>Carlo Gabriele Tocchetti</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Inflammation in cardio-oncology: beyond immunotherapies</dc:title>
<dc:identifier>pmid:38865293</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae333</dc:identifier>
</item>
<item>
<title>Reflections of an Editorial Fellow-A Window Into Medical Publishing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38865144/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jun 12. doi: 10.1001/jamacardio.2024.1330. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38865144/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38865144</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1330>10.1001/jamacardio.2024.1330</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38865144</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Vinay Guduguntla</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Reflections of an Editorial Fellow-A Window Into Medical Publishing</dc:title>
<dc:identifier>pmid:38865144</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1330</dc:identifier>
</item>
<item>
<title>Climate Change and Cardiovascular Health: A Systematic Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38865135/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Several environmental stressors that are predicted to increase in frequency and intensity with climate change are associated with increased cardiovascular risk, but data on outcomes in low-income countries are lacking. Urgent action is needed to mitigate climate change-associated cardiovascular risk, particularly in vulnerable populations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jun 12. doi: 10.1001/jamacardio.2024.1321. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Climate change may increase the risk of adverse cardiovascular outcomes by causing direct physiologic changes, psychological distress, and disruption of health-related infrastructure. Yet, the association between numerous climate change-related environmental stressors and the incidence of adverse cardiovascular events has not been systematically reviewed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To review the current evidence on the association between climate change-related environmental stressors and adverse cardiovascular outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EVIDENCE REVIEW: PubMed, Embase, Web of Science, and Cochrane Library were searched to identify peer-reviewed publications from January 1, 1970, through November 15, 2023, that evaluated associations between environmental exposures and cardiovascular mortality, acute cardiovascular events, and related health care utilization. Studies that examined only nonwildfire-sourced particulate air pollution were excluded. Two investigators independently screened 20 798 articles and selected 2564 for full-text review. Study quality was assessed using the Navigation Guide framework. Findings were qualitatively synthesized as substantial differences in study design precluded quantitative meta-analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">FINDINGS: Of 492 observational studies that met inclusion criteria, 182 examined extreme temperature, 210 ground-level ozone, 45 wildfire smoke, and 63 extreme weather events, such as hurricanes, dust storms, and droughts. These studies presented findings from 30 high-income countries, 17 middle-income countries, and 1 low-income country. The strength of evidence was rated as sufficient for extreme temperature; ground-level ozone; tropical storms, hurricanes, and cyclones; and dust storms. Evidence was limited for wildfire smoke and inadequate for drought and mudslides. Exposure to extreme temperature was associated with increased cardiovascular mortality and morbidity, but the magnitude varied with temperature and duration of exposure. Ground-level ozone amplified the risk associated with higher temperatures and vice versa. Extreme weather events, such as hurricanes, were associated with increased cardiovascular risk that persisted for many months after the initial event. Some studies noted a small increase in cardiovascular mortality, out-of-hospital cardiac arrests, and hospitalizations for ischemic heart disease after exposure to wildfire smoke, while others found no association. Older adults, racial and ethnic minoritized populations, and lower-wealth communities were disproportionately affected.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Several environmental stressors that are predicted to increase in frequency and intensity with climate change are associated with increased cardiovascular risk, but data on outcomes in low-income countries are lacking. Urgent action is needed to mitigate climate change-associated cardiovascular risk, particularly in vulnerable populations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38865135/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38865135</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1321>10.1001/jamacardio.2024.1321</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38865135</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:creator>Ethan Katznelson</dc:creator>
<dc:creator>Chia-Liang Liu</dc:creator>
<dc:creator>Nora M Al-Roub</dc:creator>
<dc:creator>Richard S Chaudhary</dc:creator>
<dc:creator>Diane E Young</dc:creator>
<dc:creator>Megan McNichol</dc:creator>
<dc:creator>Loretta J Mickley</dc:creator>
<dc:creator>Daniel B Kramer</dc:creator>
<dc:creator>Wayne E Cascio</dc:creator>
<dc:creator>Aaron S Bernstein</dc:creator>
<dc:creator>Mary B Rice</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Climate Change and Cardiovascular Health: A Systematic Review</dc:title>
<dc:identifier>pmid:38865135</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1321</dc:identifier>
</item>
<item>
<title>Postpartum Ambulatory Blood Pressure Patterns Following New-Onset Hypertensive Disorders of Pregnancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38865121/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This cohort study found that more than 80% of individuals with hypertensive disorders of pregnancy had ongoing hypertension after hospital discharge, with approximately 14% developing severe hypertension. These data support the critical role of remote BP monitoring programs and highlight the need for improved tools for risk stratification and consideration of liberalization of thresholds for medication initiation post partum.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jun 12. doi: 10.1001/jamacardio.2024.1389. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: After a hypertensive disorder of pregnancy, hypertension can worsen in the postpartum period following hospital discharge. Risk factors for ongoing hypertension and associated outcomes have not been well characterized.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To identify risk factors and characterize outcomes for individuals with ongoing hypertension and severe hypertension following hospital discharge post partum through a hospital system's remote blood pressure (BP) management program.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This cohort study involved a population-based sample of individuals with a new-onset hypertensive disorder of pregnancy (preeclampsia or gestational hypertension) and no prepregnancy hypertension who delivered between September 2019 and June 2021. Participants were enrolled in a remote BP monitoring and management program at a postpartum unit at a referral hospital. Data analysis was performed from August 2021 to January 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Inpatient postpartum BP categories.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcomes were readmission and emergency department visits within the first 6 weeks post partum. Logistic regression was used to model adjusted odds ratios (aORs) and 95% CIs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 2705 individuals in the cohort (mean [SD] age, 29.8 [5.7] years), 2214 (81.8%) had persistent hypertension post partum after hospital discharge, 382 (14.1%) developed severe hypertension after discharge, and 610 (22.6%) had antihypertensive medication initiated after discharge. Individuals with severe hypertension had increased odds of postpartum emergency department visits (aOR, 1.85; 95% CI, 1.17-2.92) and hospital readmissions (aOR, 6.75; 95% CI, 3.43-13.29) compared with individuals with BP normalization. When inpatient postpartum BP categories were compared with outpatient home BP trajectories to inform optimal thresholds for inpatient antihypertensive medication initiation, there was significant overlap between postdischarge BP trajectories among those with inpatient systolic BP greater than or equal to 140 to 149 mm Hg and/or diastolic BP greater than or equal to 90 to 99 mm Hg and those with systolic BP greater than or equal to 150 mm Hg and/or diastolic BP greater than or equal to 100 mm Hg.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This cohort study found that more than 80% of individuals with hypertensive disorders of pregnancy had ongoing hypertension after hospital discharge, with approximately 14% developing severe hypertension. These data support the critical role of remote BP monitoring programs and highlight the need for improved tools for risk stratification and consideration of liberalization of thresholds for medication initiation post partum.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38865121/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38865121</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1389>10.1001/jamacardio.2024.1389</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38865121</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Alisse Hauspurg</dc:creator>
<dc:creator>Kripa Venkatakrishnan</dc:creator>
<dc:creator>Latima Collins</dc:creator>
<dc:creator>Malamo Countouris</dc:creator>
<dc:creator>Jacob Larkin</dc:creator>
<dc:creator>Beth Quinn</dc:creator>
<dc:creator>Nuzhat Kabir</dc:creator>
<dc:creator>Janet Catov</dc:creator>
<dc:creator>Lara Lemon</dc:creator>
<dc:creator>Hyagriv Simhan</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Postpartum Ambulatory Blood Pressure Patterns Following New-Onset Hypertensive Disorders of Pregnancy</dc:title>
<dc:identifier>pmid:38865121</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1389</dc:identifier>
</item>
<item>
<title>Individual Variation in the Distribution of Apolipoprotein B Levels Across the Spectrum of LDL-C or Non-HDL-C Levels</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38865115/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This study suggests that even metabolically healthy individuals may have discordantly high apoB levels relative to LDL-C or non-HDL-C levels. The current guideline approach for apoB testing only for those with hypertriglyceridemia appears too narrow. Population percentile data can be used to translate LDL-C goals and thresholds to their apoB equivalent to facilitate clinical adoption.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jun 12. doi: 10.1001/jamacardio.2024.1310. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Although apolipoprotein B (apoB) is a superior marker of lipid-related risk compared with low-density lipoprotein cholesterol (LDL-C), few data exist to translate the goals and thresholds from LDL-C to their apoB equivalent. In addition, although current American College of Cardiology/American Heart Association guidelines provide a relative indication for apoB measurement among individuals with hypertriglyceridemia, whether discordance is limited to those subgroups is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To assess the variability in apoB level across the spectrum of LDL-C or non-high-density lipoprotein cholesterol (non-HDL-C) levels and evaluate whether discordance between apoB and LDL-C or non-HDL-C is limited to specifiable subgroups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used data from a nationally representative sample of 12 688 adult participants not using statins in the National Health and Nutrition Examination Survey between 2005 and 2016. Statistical analysis was performed from April 2023 to February 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Quantile regression was used to assess the population distribution of apoB across LDL-C or non-HDL-C levels. Discordance between apoB and LDL-C was the difference between measured apoB and median apoB levels for an individual's LDL-C level. Discordance was evaluated by age, sex, race and ethnicity, obesity, diabetes, triglyceride level, hemoglobin A1c level, body mass index (BMI), statin use, and metabolic health (defined as a BMI between 18.5 and 24.9, triglyceride level &lt;150 mg/dL, and no diabetes).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among the sample of 12 688 participants (median age, 41.0 years [IQR, 29.0-54.0 years]; 52.9% women) for LDL-C values of 55, 70, 100, and 190 mg/dL, the corresponding population median apoB levels were 49, 60, 80, and 140 mg/dL, respectively. For given levels of LDL-C, a range of apoB values was observed. At an LDL-C level of 100 mg/dL, the 95% population distribution of apoB ranged from 66 mg/dL to 99 mg/dL. ApoB variability was highest for LDL-C values estimated using the Friedewald equation, lower when using Sampson or Martin-Hopkins equations, and lowest for non-HDL-C. Although individuals with metabolic risk factors were more likely to have discordantly high apoB levels (ie, had higher median observed apoB levels relative to what was estimated based on LDL-C), significant variability in apoB levels was observed even among metabolically healthy individuals.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This study suggests that even metabolically healthy individuals may have discordantly high apoB levels relative to LDL-C or non-HDL-C levels. The current guideline approach for apoB testing only for those with hypertriglyceridemia appears too narrow. Population percentile data can be used to translate LDL-C goals and thresholds to their apoB equivalent to facilitate clinical adoption.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38865115/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38865115</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1310>10.1001/jamacardio.2024.1310</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38865115</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Ahmed Sayed</dc:creator>
<dc:creator>Eric D Peterson</dc:creator>
<dc:creator>Salim S Virani</dc:creator>
<dc:creator>Allan D Sniderman</dc:creator>
<dc:creator>Ann Marie Navar</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Individual Variation in the Distribution of Apolipoprotein B Levels Across the Spectrum of LDL-C or Non-HDL-C Levels</dc:title>
<dc:identifier>pmid:38865115</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1310</dc:identifier>
</item>
<item>
<title>Postpartum Remote Blood Pressure Monitoring-When Control Is of the Essence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38865113/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jun 12. doi: 10.1001/jamacardio.2024.1386. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38865113/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38865113</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1386>10.1001/jamacardio.2024.1386</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38865113</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Postpartum Remote Blood Pressure Monitoring-When Control Is of the Essence</dc:title>
<dc:identifier>pmid:38865113</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1386</dc:identifier>
</item>
<item>
<title>Plasma Proteomics of Exercise Blood Pressure and Incident Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38865108/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Plasma proteomic profiling of EBP identified a novel protein, TGFBR3, which may protect against elevated BP and long-term CVD outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jun 12. doi: 10.1001/jamacardio.2024.1397. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Blood pressure response during acute exercise (exercise blood pressure [EBP]) is associated with the future risk of hypertension and cardiovascular disease (CVD). Biochemical characterization of EBP could inform disease biology and identify novel biomarkers of future hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To identify protein markers associated with EBP and test their association with incident hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This study assayed 4977 plasma proteins in 681 healthy participants (from 763 assessed) of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE; data collection from January 1993 to December 1997 and plasma proteomics from January 2019 to January 2020) Family Study at rest who underwent 2 cardiopulmonary exercise tests. Individuals were free of CVD at the time of recruitment. Individuals with resting SBP ≥160 mm Hg or DBP ≥100 mm Hg or taking antihypertensive drug therapy were excluded from the study. The association between resting plasma protein levels to both resting BP and EBP was evaluated. Proteins associated with EBP were analyzed for their association with incident hypertension in the Framingham Heart Study (FHS; n = 1177) and validated in the Jackson Heart Study (JHS; n = 772) and Multi-Ethnic Study of Atherosclerosis (MESA; n = 1367). Proteins associated with incident hypertension were tested for putative causal links in approximately 700 000 individuals using cis-protein quantitative loci mendelian randomization (cis-MR). Data were analyzed from January 2023 to January 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Plasma proteins.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: EBP was defined as the BP response during a fixed workload (50 W) on a cycle ergometer. Hypertension was defined as BP ≥140/90 mm Hg or taking antihypertensive medication.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among the 681 participants in the HERITAGE Family Study, the mean (SD) age was 34 (13) years; 366 participants (54%) were female; 238 (35%) were self-reported Black and 443 (65%) were self-reported White. Proteomic profiling of EBP revealed 34 proteins that would not have otherwise been identified through profiling of resting BP alone. Transforming growth factor β receptor 3 (TGFBR3) and prostaglandin D2 synthase (PTGDS) had the strongest association with exercise systolic BP (SBP) and diastolic BP (DBP), respectively (TGFBR3: exercise SBP, β estimate, -3.39; 95% CI, -4.79 to -2.00; P = 2.33 × 10-6; PTGDS: exercise DBP β estimate, -2.50; 95% CI, -3.29 to -1.70; P = 1.18 × 10-9). In fully adjusted models, TGFBR3 was inversely associated with incident hypertension in FHS, JHS, and MESA (hazard ratio [HR]: FHS, 0.86; 95% CI, 0.75-0.97; P = .01; JHS, 0.87; 95% CI, 0.77-0.97; P = .02; MESA, 0.84; 95% CI, 0.71-0.98; P = .03; pooled cohort, 0.86; 95% CI, 0.79-0.92; P = 6 × 10-5). Using cis-MR, genetically predicted levels of TGFBR3 were associated with SBP, hypertension, and CVD events (SBP: β, -0.38; 95% CI, -0.64 to -0.11; P = .006; hypertension: odds ratio [OR], 0.99; 95% CI, 0.98-0.99; P &lt; .001; heart failure with hypertension: OR, 0.86; 95% CI, 0.77-0.97; P = .01; CVD: OR, 0.84; 95% CI, 0.77-0.92; P = 8 × 10-5; cerebrovascular events: OR, 0.77; 95% CI, 0.70-0.85; P = 5 × 10-7).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Plasma proteomic profiling of EBP identified a novel protein, TGFBR3, which may protect against elevated BP and long-term CVD outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38865108/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38865108</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1397>10.1001/jamacardio.2024.1397</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38865108</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Prashant Rao</dc:creator>
<dc:creator>Michelle J Keyes</dc:creator>
<dc:creator>Michael Y Mi</dc:creator>
<dc:creator>Jacob L Barber</dc:creator>
<dc:creator>Usman A Tahir</dc:creator>
<dc:creator>Shuliang Deng</dc:creator>
<dc:creator>Clary B Clish</dc:creator>
<dc:creator>Dongxiao Shen</dc:creator>
<dc:creator>Laurie A Farrell</dc:creator>
<dc:creator>James G Wilson</dc:creator>
<dc:creator>Yan Gao</dc:creator>
<dc:creator>Wondwosen K Yimer</dc:creator>
<dc:creator>Lynette Ekunwe</dc:creator>
<dc:creator>Michael E Hall</dc:creator>
<dc:creator>Paul M Muntner</dc:creator>
<dc:creator>Xiuqing Guo</dc:creator>
<dc:creator>Kent D Taylor</dc:creator>
<dc:creator>Russell P Tracy</dc:creator>
<dc:creator>Stephen S Rich</dc:creator>
<dc:creator>Jerome I Rotter</dc:creator>
<dc:creator>Vanessa Xanthakis</dc:creator>
<dc:creator>Ramachandran S Vasan</dc:creator>
<dc:creator>Claude Bouchard</dc:creator>
<dc:creator>Mark A Sarzynski</dc:creator>
<dc:creator>Robert E Gerszten</dc:creator>
<dc:creator>Jeremy M Robbins</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Plasma Proteomics of Exercise Blood Pressure and Incident Hypertension</dc:title>
<dc:identifier>pmid:38865108</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1397</dc:identifier>
</item>
<item>
<title>Pulsed Field vs Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: Recurrent Atrial Arrhythmia Burden</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38864538/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION: Compared to thermal ablation, PFA more often resulted in an AA burden less than the clinically-significant threshold of 0.1% burden.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 6:S0735-1097(24)07133-X. doi: 10.1016/j.jacc.2024.05.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The ADVENT randomized trial revealed no significant difference in 1-year freedom from atrial arrhythmias (AA) between thermal (RF/Cryo) and pulsed field ablation (PFA). However, recent studies indicate that the post-ablation AA burden is a better predictor of clinical outcomes than the dichotomous endpoint of 30-second AA recurrence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To determine i) the impact of post-ablation AA burden on outcomes, and ii) the effect of ablation modality on AA burden.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In ADVENT, symptomatic drug-refractory paroxysmal AF (PAF) patients underwent PFA or thermal ablation. Post-ablation transtelephonic ECG monitor (TTM) recordings were collected weekly or for symptoms, and 72-hour Holters were at 6- and 12-months. AA burden was calculated from percentage AA on Holters and TTMs. Quality-of-life assessments were at baseline and 12-months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From 593 randomized patients (299 PFA, 294 thermal), using aggregate PFA/thermal data, an AA burden exceeding 0.1% was associated with a significantly reduced quality-of-life and an increase in clinical interventions: redo ablation, cardioversion and hospitalization. There were more patients with residual AA burden &lt;0.1% with PFA than thermal ablation (OR 1.5, 95%CI: 1.0, 2.3; p=0.04). Evaluation of outcomes by baseline demographics revealed that patients with prior failed Class I/III AADs had less residual AA burden after PFA compared to thermal ablation (OR 2.5, 95%CI: 1.4, 4.3; p=0.002); patients receiving only Class II/IV AADs pre-ablation had no difference in AA burden between ablation groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: Compared to thermal ablation, PFA more often resulted in an AA burden less than the clinically-significant threshold of 0.1% burden.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38864538/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38864538</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.001>10.1016/j.jacc.2024.05.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38864538</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Vivek Y Reddy</dc:creator>
<dc:creator>Moussa Mansour</dc:creator>
<dc:creator>Hugh Calkins</dc:creator>
<dc:creator>Andre d'Avila</dc:creator>
<dc:creator>Larry Chinitz</dc:creator>
<dc:creator>Christopher Woods</dc:creator>
<dc:creator>Sanjaya K Gupta</dc:creator>
<dc:creator>Jamie Kim</dc:creator>
<dc:creator>Zayd A Eldadah</dc:creator>
<dc:creator>Robert A Pickett</dc:creator>
<dc:creator>Jeffrey Winterfield</dc:creator>
<dc:creator>Wilber W Su</dc:creator>
<dc:creator>Jonathan W Waks</dc:creator>
<dc:creator>Christopher W Schneider</dc:creator>
<dc:creator>Elizabeth Richards</dc:creator>
<dc:creator>Elizabeth M Albrecht</dc:creator>
<dc:creator>Brad S Sutton</dc:creator>
<dc:creator>Edward P Gerstenfeld</dc:creator>
<dc:creator>ADVENT Investigators</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Pulsed Field vs Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: Recurrent Atrial Arrhythmia Burden</dc:title>
<dc:identifier>pmid:38864538</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.001</dc:identifier>
</item>
<item>
<title>Therapeutic Inhibition of &lt;em>;LincRNA-p21&lt;/em>; Protects Against Cardiac Hypertrophy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38864216/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings advance our understanding of the functional significance of stress-induced long noncoding RNA in cardiac hypertrophy and demonstrate the potential of lincRNA-p21 as a novel therapeutic target for cardiac hypertrophy and subsequent heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 12. doi: 10.1161/CIRCRESAHA.123.323356. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac hypertrophy is an adaptive response to pressure overload aimed at maintaining cardiac function. However, prolonged hypertrophy significantly increases the risk of maladaptive cardiac remodeling and heart failure. Recent studies have implicated long noncoding RNAs in cardiac hypertrophy and cardiomyopathy, but their significance and mechanism(s) of action are not well understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We measured <i>lincRNA-p21</i> RNA and H3K27ac levels in the hearts of dilated cardiomyopathy patients. We assessed the functional role of <i>lincRNA-p21</i> in basal and surgical pressure-overload conditions using loss-of-function mice. Genome-wide transcriptome analysis revealed dysregulated genes and pathways. We labeled proteins in proximity to full-length <i>lincRNA-p21</i> using a novel BioID2-based system. We immunoprecipitated <i>lincRNA-p21</i>-interacting proteins and performed cell fractionation, ChIP-seq (chromatin immunoprecipitation followed by sequencing), and co-immunoprecipitation to investigate molecular interactions and underlying mechanisms. We used GapmeR antisense oligonucleotides to evaluate the therapeutic potential of <i>lincRNA-p21</i> inhibition in cardiac hypertrophy and associated heart failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: <i>lincRNA-p21</i> was induced in mice and humans with cardiomyopathy. Global and cardiac-specific <i>lincRNA-p21</i> knockout significantly suppressed pressure overload-induced ventricular wall thickening, stress marker elevation, and deterioration of cardiac function. Genome-wide transcriptome analysis and transcriptional network analysis revealed that <i>lincRNA-p21</i> acts <i>in trans</i> to stimulate the NFAT/MEF2 pathway. Mechanistically, <i>lincRNA-p21</i> is bound to the scaffold protein KAP1. <i>lincRNA-p21</i> cardiac-specific knockout suppressed stress-induced nuclear accumulation of KAP1, and KAP1 knockdown attenuated cardiac hypertrophy and NFAT activation. KAP1 positively regulates pathological hypertrophy by physically interacting with NFATC4 to promote the overactive status of NFAT/MEF2 signaling. GapmeR antisense oligonucleotide depletion of <i>lincRNA-p21</i> similarly inhibited cardiac hypertrophy and adverse remodeling, highlighting the therapeutic potential of inhibiting <i>lincRNA-p21</i>.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings advance our understanding of the functional significance of stress-induced long noncoding RNA in cardiac hypertrophy and demonstrate the potential of <i>lincRNA-p21</i> as a novel therapeutic target for cardiac hypertrophy and subsequent heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38864216/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38864216</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323356>10.1161/CIRCRESAHA.123.323356</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38864216</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Yi Wang</dc:creator>
<dc:creator>Mingming Zhang</dc:creator>
<dc:creator>Rong Wang</dc:creator>
<dc:creator>Jing Lin</dc:creator>
<dc:creator>Qing Ma</dc:creator>
<dc:creator>Haipeng Guo</dc:creator>
<dc:creator>Huihui Huang</dc:creator>
<dc:creator>Zhuomin Liang</dc:creator>
<dc:creator>Yangpo Cao</dc:creator>
<dc:creator>Xiaoran Zhang</dc:creator>
<dc:creator>Yao Wei Lu</dc:creator>
<dc:creator>Jianming Liu</dc:creator>
<dc:creator>Feng Xiao</dc:creator>
<dc:creator>Hualin Yan</dc:creator>
<dc:creator>Nadya Dimitrova</dc:creator>
<dc:creator>Zhan-Peng Huang</dc:creator>
<dc:creator>John D Mably</dc:creator>
<dc:creator>William T Pu</dc:creator>
<dc:creator>Da-Zhi Wang</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Therapeutic Inhibition of &lt;em>;LincRNA-p21&lt;/em>; Protects Against Cardiac Hypertrophy</dc:title>
<dc:identifier>pmid:38864216</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323356</dc:identifier>
</item>
<item>
<title>Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38864173/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Continuous optimization of guideline-recommended medical therapy for at least 180 days in HFrEF is associated with additional LVEF improvement >; 35%, allowing for better decision-making regarding preventive implantable cardioverter-defibrillator therapy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 12:ehae334. doi: 10.1093/eurheartj/ehae334. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: In patients with de novo heart failure with reduced ejection fraction (HFrEF), improvement of left ventricular ejection fraction (LVEF) is expected to occur when started on guideline-recommended medical therapy. However, improvement may not be completed within 90 days.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with HFrEF and LVEF ≤ 35% prescribed a wearable cardioverter-defibrillator between 2017 and 2022 from 68 sites were enrolled, starting with a registry phase for 3 months and followed by a study phase up to 1 year. The primary endpoints were LVEF improvement >; 35% between Days 90 and 180 following guideline-recommended medical therapy initiation and the percentage of target dose reached at Days 90 and 180.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 598 patients with de novo HFrEF [59 years (interquartile range 51-68), 27% female] entered the study phase. During the first 180 days, a significant increase in dosage of beta-blockers, renin-angiotensin system inhibitors, and mineralocorticoid receptor antagonists was observed (P &lt; .001). At Day 90, 46% [95% confidence interval (CI) 41%-50%] of study phase patients had LVEF improvement >; 35%; 46% (95% CI 40%-52%) of those with persistently low LVEF at Day 90 had LVEF improvement >; 35% by Day 180, increasing the total rate of improvement >; 35% to 68% (95% CI 63%-72%). In 392 patients followed for 360 days, improvement >; 35% was observed in 77% (95% CI 72%-81%) of the patients. Until Day 90, sustained ventricular tachyarrhythmias were observed in 24 wearable cardioverter-defibrillator carriers (1.8%). After 90 days, no sustained ventricular tachyarrhythmia occurred in wearable cardioverter-defibrillator carriers.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Continuous optimization of guideline-recommended medical therapy for at least 180 days in HFrEF is associated with additional LVEF improvement >; 35%, allowing for better decision-making regarding preventive implantable cardioverter-defibrillator therapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38864173/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38864173</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae334>10.1093/eurheartj/ehae334</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38864173</guid>
<pubDate>Wed, 12 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Christian Veltmann</dc:creator>
<dc:creator>David Duncker</dc:creator>
<dc:creator>Michael Doering</dc:creator>
<dc:creator>Siva Gummadi</dc:creator>
<dc:creator>Michael Robertson</dc:creator>
<dc:creator>Thomas Wittlinger</dc:creator>
<dc:creator>Byron J Colley</dc:creator>
<dc:creator>Christian Perings</dc:creator>
<dc:creator>Orvar Jonsson</dc:creator>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:creator>Robert Sanchez</dc:creator>
<dc:creator>Lars S Maier</dc:creator>
<dc:date>2024-06-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study</dc:title>
<dc:identifier>pmid:38864173</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae334</dc:identifier>
</item>
<item>
<title>Modulation of FGF pathway signaling and vascular differentiation using designed oligomeric assemblies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38861993/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>Many growth factors and cytokines signal by binding to the extracellular domains of their receptors and driving association and transphosphorylation of the receptor intracellular tyrosine kinase domains, initiating downstream signaling cascades. To enable systematic exploration of how receptor valency and geometry affect signaling outcomes, we designed cyclic homo-oligomers with up to 8 subunits using repeat protein building blocks that can be modularly extended. By incorporating a de...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 7:S0092-8674(24)00534-8. doi: 10.1016/j.cell.2024.05.025. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Many growth factors and cytokines signal by binding to the extracellular domains of their receptors and driving association and transphosphorylation of the receptor intracellular tyrosine kinase domains, initiating downstream signaling cascades. To enable systematic exploration of how receptor valency and geometry affect signaling outcomes, we designed cyclic homo-oligomers with up to 8 subunits using repeat protein building blocks that can be modularly extended. By incorporating a de novo-designed fibroblast growth factor receptor (FGFR)-binding module into these scaffolds, we generated a series of synthetic signaling ligands that exhibit potent valency- and geometry-dependent Ca<sup>2+</sup> release and mitogen-activated protein kinase (MAPK) pathway activation. The high specificity of the designed agonists reveals distinct roles for two FGFR splice variants in driving arterial endothelium and perivascular cell fates during early vascular development. Our designed modular assemblies should be broadly useful for unraveling the complexities of signaling in key developmental transitions and for developing future therapeutic applications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38861993/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38861993</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.025>10.1016/j.cell.2024.05.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38861993</guid>
<pubDate>Tue, 11 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Natasha I Edman</dc:creator>
<dc:creator>Ashish Phal</dc:creator>
<dc:creator>Rachel L Redler</dc:creator>
<dc:creator>Thomas Schlichthaerle</dc:creator>
<dc:creator>Sanjay R Srivatsan</dc:creator>
<dc:creator>Devon Duron Ehnes</dc:creator>
<dc:creator>Ali Etemadi</dc:creator>
<dc:creator>Seong J An</dc:creator>
<dc:creator>Andrew Favor</dc:creator>
<dc:creator>Zhe Li</dc:creator>
<dc:creator>Florian Praetorius</dc:creator>
<dc:creator>Max Gordon</dc:creator>
<dc:creator>Thomas Vincent</dc:creator>
<dc:creator>Silvia Marchiano</dc:creator>
<dc:creator>Leslie Blakely</dc:creator>
<dc:creator>Chuwei Lin</dc:creator>
<dc:creator>Wei Yang</dc:creator>
<dc:creator>Brian Coventry</dc:creator>
<dc:creator>Derrick R Hicks</dc:creator>
<dc:creator>Longxing Cao</dc:creator>
<dc:creator>Neville Bethel</dc:creator>
<dc:creator>Piper Heine</dc:creator>
<dc:creator>Analisa Murray</dc:creator>
<dc:creator>Stacey Gerben</dc:creator>
<dc:creator>Lauren Carter</dc:creator>
<dc:creator>Marcos Miranda</dc:creator>
<dc:creator>Babak Negahdari</dc:creator>
<dc:creator>Sangwon Lee</dc:creator>
<dc:creator>Cole Trapnell</dc:creator>
<dc:creator>Ying Zheng</dc:creator>
<dc:creator>Charles E Murry</dc:creator>
<dc:creator>Devin K Schweppe</dc:creator>
<dc:creator>Benjamin S Freedman</dc:creator>
<dc:creator>Lance Stewart</dc:creator>
<dc:creator>Damian C Ekiert</dc:creator>
<dc:creator>Joseph Schlessinger</dc:creator>
<dc:creator>Jay Shendure</dc:creator>
<dc:creator>Gira Bhabha</dc:creator>
<dc:creator>Hannele Ruohola-Baker</dc:creator>
<dc:creator>David Baker</dc:creator>
<dc:date>2024-06-11</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Modulation of FGF pathway signaling and vascular differentiation using designed oligomeric assemblies</dc:title>
<dc:identifier>pmid:38861993</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.025</dc:identifier>
</item>
<item>
<title>Pulmonary artery pseudoaneurysm due to COVID-19-associated pulmonary mucormycosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38860736/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 11:ehae355. doi: 10.1093/eurheartj/ehae355. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38860736/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38860736</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae355>10.1093/eurheartj/ehae355</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38860736</guid>
<pubDate>Tue, 11 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Zihao Li</dc:creator>
<dc:creator>Hongwei Zhang</dc:creator>
<dc:creator>Zhenhe Liu</dc:creator>
<dc:date>2024-06-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pulmonary artery pseudoaneurysm due to COVID-19-associated pulmonary mucormycosis</dc:title>
<dc:identifier>pmid:38860736</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae355</dc:identifier>
</item>
<item>
<title>Brugada syndrome: can polygenic risk scores help the clinician?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38860730/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 11:ehae364. doi: 10.1093/eurheartj/ehae364. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38860730/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38860730</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae364>10.1093/eurheartj/ehae364</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38860730</guid>
<pubDate>Tue, 11 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Elijah R Behr</dc:creator>
<dc:date>2024-06-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Brugada syndrome: can polygenic risk scores help the clinician?</dc:title>
<dc:identifier>pmid:38860730</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae364</dc:identifier>
</item>
<item>
<title>Challenge-skill balance in cardiac surgery: an attempt to explain sex-related differences in coronary surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38860698/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 11:ehae350. doi: 10.1093/eurheartj/ehae350. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38860698/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38860698</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae350>10.1093/eurheartj/ehae350</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38860698</guid>
<pubDate>Tue, 11 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Torsten Doenst</dc:creator>
<dc:creator>Gloria Faerber</dc:creator>
<dc:date>2024-06-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Challenge-skill balance in cardiac surgery: an attempt to explain sex-related differences in coronary surgery</dc:title>
<dc:identifier>pmid:38860698</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae350</dc:identifier>
</item>
<item>
<title>Accelerated high sensitivity troponin diagnostics: ready for an even faster pace?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38860689/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 11:ehae344. doi: 10.1093/eurheartj/ehae344. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38860689/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38860689</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae344>10.1093/eurheartj/ehae344</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38860689</guid>
<pubDate>Tue, 11 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Evangelos Giannitsis</dc:creator>
<dc:creator>Norbert Frey</dc:creator>
<dc:creator>Hugo A Katus</dc:creator>
<dc:date>2024-06-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Accelerated high sensitivity troponin diagnostics: ready for an even faster pace?</dc:title>
<dc:identifier>pmid:38860689</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae344</dc:identifier>
</item>
<item>
<title>CD163&lt;sup>;+&lt;/sup>; Macrophages Induce Endothelial-to-Mesenchymal Transition in Atheroma</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38860377/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: CD163^(+) macrophages provoke EndMT, which may promote plaque progression through fibrous cap thinning.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 11. doi: 10.1161/CIRCRESAHA.123.324082. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cell phenotype switching is increasingly being recognized in atherosclerosis. However, our understanding of the exact stimuli for such cellular transformations and their significance for human atherosclerosis is still evolving. Intraplaque hemorrhage is thought to be a major contributor to plaque progression in part by stimulating the influx of CD163<sup>+</sup> macrophages. Here, we explored the hypothesis that CD163 macrophages cause plaque progression through the induction of proapoptotic endothelial-to-mesenchymal transition (EndMT) within the fibrous cap.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Human coronary artery sections from CVPath's autopsy registry were selected for pathological analysis. Athero-prone <i>ApoE</i><sup><i>-/-</i></sup> and <i>ApoE</i><sup><i>-/-</i></sup><i>/CD163</i><sup><i>-/-</i></sup> mice were used for in vivo studies. Human peripheral blood mononuclear cell-induced macrophages and human aortic endothelial cells were used for in vitro experiments.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In 107 lesions with acute coronary plaque rupture, 55% had pathological evidence of intraplaque hemorrhage in nonculprit vessels/lesions. Thinner fibrous cap, greater CD163<sup>+</sup> macrophage accumulation, and a larger number of CD31/FSP-1 (fibroblast specific protein-1) double-positive cells and TUNEL positive cells in the fibrous cap were observed in nonculprit intraplaque hemorrhage lesions, as well as in culprit rupture sections versus nonculprit fibroatheroma sections. Human aortic endothelial cells cultured with supernatants from hemoglobin/haptoglobin-exposed macrophages showed that increased mesenchymal marker proteins (transgelin and FSP-1) while endothelial markers (VE-cadherin and CD31) were reduced, suggesting EndMT induction. Activation of NF-κB (nuclear factor kappa β) signaling by proinflammatory cytokines released from CD163<sup>+</sup> macrophages directly regulated the expression of Snail, a critical transcription factor during EndMT induction. Western blot analysis for cleaved caspase 3 and microarray analysis of human aortic endothelial cells indicated that apoptosis was stimulated during CD163<sup>+</sup> macrophage-induced EndMT. Additionally, <i>CD163</i> deletion in athero-prone mice suggested that CD163 is required for EndMT and plaque progression. Using single-cell RNA sequencing from human carotid endarterectomy lesions, a population of EndMT was detected, which demonstrated significant upregulation of apoptosis-related genes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CD163<sup>+</sup> macrophages provoke EndMT, which may promote plaque progression through fibrous cap thinning.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38860377/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38860377</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324082>10.1161/CIRCRESAHA.123.324082</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38860377</guid>
<pubDate>Tue, 11 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Masayuki Mori</dc:creator>
<dc:creator>Atsushi Sakamoto</dc:creator>
<dc:creator>Rika Kawakami</dc:creator>
<dc:creator>Liang Guo</dc:creator>
<dc:creator>Lotte Slenders</dc:creator>
<dc:creator>Jose Verdezoto Mosquera</dc:creator>
<dc:creator>Saikat Kumar B Ghosh</dc:creator>
<dc:creator>Marian Wesseling</dc:creator>
<dc:creator>Tatsuya Shiraki</dc:creator>
<dc:creator>Arielle Bellissard</dc:creator>
<dc:creator>Palak Shah</dc:creator>
<dc:creator>Craig C Weinkauf</dc:creator>
<dc:creator>Takao Konishi</dc:creator>
<dc:creator>Yu Sato</dc:creator>
<dc:creator>Anne Cornelissen</dc:creator>
<dc:creator>Kenji Kawai</dc:creator>
<dc:creator>Hiroyuki Jinnouchi</dc:creator>
<dc:creator>Weili Xu</dc:creator>
<dc:creator>Aimee E Vozenilek</dc:creator>
<dc:creator>Desiree Williams</dc:creator>
<dc:creator>Takamasa Tanaka</dc:creator>
<dc:creator>Teruo Sekimoto</dc:creator>
<dc:creator>Michael C Kelly</dc:creator>
<dc:creator>Raquel Fernandez</dc:creator>
<dc:creator>Alyssa Grogan</dc:creator>
<dc:creator>A J Coslet</dc:creator>
<dc:creator>Alisa Fedotova</dc:creator>
<dc:creator>Anjali Kurse</dc:creator>
<dc:creator>Michal Mokry</dc:creator>
<dc:creator>Maria E Romero</dc:creator>
<dc:creator>Frank D Kolodgie</dc:creator>
<dc:creator>Gerard Pasterkamp</dc:creator>
<dc:creator>Clint L Miller</dc:creator>
<dc:creator>Renu Virmani</dc:creator>
<dc:creator>Aloke V Finn</dc:creator>
<dc:date>2024-06-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>CD163&lt;sup>;+&lt;/sup>; Macrophages Induce Endothelial-to-Mesenchymal Transition in Atheroma</dc:title>
<dc:identifier>pmid:38860377</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324082</dc:identifier>
</item>
<item>
<title>Predicting Out-of-Hospital Cardiac Arrest in the General Population Using Electronic Health Records</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38860364/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240612222710&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In a population-based case-control study, machine learning models incorporating readily available EHR data showed reasonable discrimination and risk enrichment for OHCA in the general population. Salient factors associated with OCHA risk were myriad across the cardiovascular and noncardiovascular spectrum. Public health and tailored strategies for OHCA prediction and prevention will require incorporation of this complexity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 11. doi: 10.1161/CIRCULATIONAHA.124.069105. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The majority of out-of-hospital cardiac arrests (OHCAs) occur among individuals in the general population, for whom there is no established strategy to identify risk. In this study, we assess the use of electronic health record (EHR) data to identify OHCA in the general population and define salient factors contributing to OHCA risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The analytical cohort included 2366 individuals with OHCA and 23 660 age- and sex-matched controls receiving health care at the University of Washington. Comorbidities, electrocardiographic measures, vital signs, and medication prescription were abstracted from the EHR. The primary outcome was OHCA. Secondary outcomes included shockable and nonshockable OHCA. Model performance including area under the receiver operating characteristic curve and positive predictive value were assessed and adjusted for observed rate of OHCA across the health system.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: There were significant differences in demographic characteristics, vital signs, electrocardiographic measures, comorbidities, and medication distribution between individuals with OHCA and controls. In external validation, discrimination in machine learning models (area under the receiver operating characteristic curve 0.80-0.85) was superior to a baseline model with conventional cardiovascular risk factors (area under the receiver operating characteristic curve 0.66). At a specificity threshold of 99%, correcting for baseline OHCA incidence across the health system, positive predictive value was 2.5% to 3.1% in machine learning models compared with 0.8% for the baseline model. Longer corrected QT interval, substance abuse disorder, fluid and electrolyte disorder, alcohol abuse, and higher heart rate were identified as salient predictors of OHCA risk across all machine learning models. Established cardiovascular risk factors retained predictive importance for shockable OHCA, but demographic characteristics (minority race, single marital status) and noncardiovascular comorbidities (substance abuse disorder) also contributed to risk prediction. For nonshockable OHCA, a range of salient predictors, including comorbidities, habits, vital signs, demographic characteristics, and electrocardiographic measures, were identified.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In a population-based case-control study, machine learning models incorporating readily available EHR data showed reasonable discrimination and risk enrichment for OHCA in the general population. Salient factors associated with OCHA risk were myriad across the cardiovascular and noncardiovascular spectrum. Public health and tailored strategies for OHCA prediction and prevention will require incorporation of this complexity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38860364/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240612222710&v=2.18.0.post9+e462414">38860364</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069105>10.1161/CIRCULATIONAHA.124.069105</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38860364</guid>
<pubDate>Tue, 11 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Jessica Perry</dc:creator>
<dc:creator>Jennifer A Brody</dc:creator>
<dc:creator>Christine Fong</dc:creator>
<dc:creator>Jacob E Sunshine</dc:creator>
<dc:creator>Vikas N O'Reilly-Shah</dc:creator>
<dc:creator>Michael R Sayre</dc:creator>
<dc:creator>Thomas D Rea</dc:creator>
<dc:creator>Noah Simon</dc:creator>
<dc:creator>Ali Shojaie</dc:creator>
<dc:creator>Nona Sotoodehnia</dc:creator>
<dc:creator>Neal A Chatterjee</dc:creator>
<dc:date>2024-06-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Predicting Out-of-Hospital Cardiac Arrest in the General Population Using Electronic Health Records</dc:title>
<dc:identifier>pmid:38860364</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069105</dc:identifier>
</item>





























</channel>
</rss>